Neomycin Sulfate Tablets — Class II drug recall D-1473-2022
Terminated recall by Teva Pharmaceuticals USA Inc, reported 2022-09-07, distributed nationwide. CGMP Deviations: A foreign matter identified as teflon was found in the Active Pharmaceutical Ingredient (API)
| Recall number | D-1473-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA Inc, Parsippany, NJ, United States |
| Recall initiated | 2022-08-23 |
| Classified | 2022-08-30 |
| Reported by FDA | 2022-09-07 |
| Terminated | 2023-09-07 |
| Distributed | Nationwide (US) |
| Reason classes | foreign material, cgmp |
| NDC | 00093-1177, 00093-1177-01 |
| Lot numbers | 3007746, 3007829, 3007830 |
| Expiration dates | 2024-10 |
Product
Neomycin Sulfate Tablets, USP 500 mg , 100-count bottles, Rx only, Distributed by: TEVA PHARMACEUTICALS USA, INC North Wales, PA 19454, NDC 0093-1177-01
Reason for recall
CGMP Deviations: A foreign matter identified as teflon was found in the Active Pharmaceutical Ingredient (API) used in the manufacture of Neomycin Sulfate Tablets, USP 500 mg.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1473-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.